OncoMatch/Clinical Trials/NCT06615193
A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
Is NCT06615193 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies HDM2005 for advanced solid tumors.
Treatment: HDM2005 — This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: ROR1 expression
ROR1 expression testing at the central laboratory
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06615193 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ROR1?
Yes, ROR1 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify